Damora Therapeutics
DMRA
10 hedge funds and large institutions have $1.56M invested in Damora Therapeutics in 2024 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 14 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 2
4.6% less ownership
Funds ownership: 14.89% → 10.29% (-4.6%)
18% less capital invested
Capital invested by funds: $1.91M → $1.56M (-$351K)
55% less funds holding
Funds holding: 22 → 10 (-12)
86% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$66.5K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
+$2.68K |
| 3 |
Morgan Stanley
New York
|
+$522 |
| 4 |
DB
Danske Bank
Copenhagen K,
Denmark
|
+$91 |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$26 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$105K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
-$102K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$79.8K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$61K |
| 5 |
Renaissance Technologies
New York
|
-$23.4K |
DMRA Hedge Fund Activity: Q3 2024 in Review
10 of the 6,978 institutional investors tracked by Wall St. Rank reported a position in Damora Therapeutics (DMRA) for Q3 2024, worth a combined $1.56M — down 18% from $1.91M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of DMRA and 2 opened new positions — a net loss of 12 holders — while 2 trimmed existing stakes and 4 added.
The largest buyer was UBS Group, opening a new position worth an estimated $66.5K. The largest seller was Vanguard Group, exiting entirely with an estimated $105K sold.
- 10 institutional investors held Damora Therapeutics (DMRA) as of Q3 2024, down from 22 in Q2 2024.
- Funds reported $1.56M of Damora Therapeutics stock for Q3 2024, down 18% quarter-over-quarter.
- 2 funds opened new Damora Therapeutics positions in Q3 2024 and 14 closed out, a net change of -12 holders.
- The largest Damora Therapeutics buyer in Q3 2024 was UBS Group, an estimated $66.5K added.
- The largest Damora Therapeutics seller in Q3 2024 was Vanguard Group, an estimated $105K sold.
Based on aggregated 13F filings for Q3 2024.